Switching from natalizumab to fingolimodLudwig Kappos, Athanasios P. Kyritsis, Ernst‐Wilhelm Radue et al.|Neurology|2015Cited by 116
Safety and efficacy of MD1003 (high-dose biotin) in patients with progressive multiple sclerosis (SPI2): a randomised, double-blind, placebo-controlled, phase 3 trialBruce Cree, Piotr Sokolowski, Gary Cutter et al.|The Lancet Neurology|2020Cited by 104
Rituximab vs Ocrelizumab in Relapsing-Remitting Multiple SclerosisIzanne Roos, Vincent Van Pesch, Anneke van der Walt et al.|JAMA Neurology|2023Cited by 62
Guillain‐Barré syndrome following pandemic (H1N1) 2009 influenza A immunisation in Victoria: a self‐controlled case seriesNigel W. Crawford, Lynette Kiers, Allen Cheng et al.|The Medical Journal of Australia|2012Cited by 33
Neuroimaging characteristics may aid in diagnosis, subtyping, and prognosis in autoimmune encephalitisJames Broadley, Meaghan Clough, Robb Wesselingh et al.|Neurological Sciences|2022Cited by 4